Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19

UK cohort study (n=13,202 on NSAIDs, n=12,457 on comparator drugs) found no increase in risk of suspected or confirmed COVID‐19 (HR 0.79; 95% CI 0.57–1.11) or mortality (0.85; 0.61–1.20), among patients with OA in a primary care setting prescribed NSAIDs vs comparator drugs.

Source:

Arthritis & Rheumatology